Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about REVB, unsubscribe in one click. Privacy
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Intravenous Gemini | Renal Insufficiency, Chronic | Phase 1/2 · NCT06863467 | Completed |
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
REVB holds $11.5M in cash and short-term investments (as of Jun 30, 2026) and burns about $2.9M/quarter from operations, an estimated runway of 11.9 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 65 · High
The Company does not anticipate that its current cash and cash equivalents balance will be sufficient to sustain operations within one year after the date that the Company’s unaudited condensed financial statements for June 30, 2026 were issued, which raises substantial doubt about its ability to continue as a going co10-Q, Aug 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when REVB files for a raise →
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for REVB and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →